Our achievements. Our accomplishments. Our impact.



  • Till & McCulloch Meetings

    The Stem Cell Network’s Annual General Meeting, which metamorphosed into the Till & McCulloch Meetings, is a one-of-a-kind venue for trainees and young scientists to network and gain experience in the competitive field of regenerative medicine.

    READ STORY

  • Commercialization

    The Stem Cell Network’s catalysis of commercialization of stem cell research has led to 399 patent applications, 60 issued patents, 43 licenses granted, the growth or launch of 11 start-up biotechnology companies and the establishment of a new Centre for the Commercialization of Regenerative Medicine (CCRM) to develop a strong industry presence in several emerging technology areas likely to be crucial to the future delivery of stem cell-based therapies.

    READ STORY

  • Drug Discovery and Repurposing

    The Stem Cell Network was among the first organizations to recognize the potential of using stem cells for drug repositioning and discovery in order to reduce time and costs of bringing new therapies to patients, and in the process has established Canada as a world leader in the field.

    READ STORY

  • Stem Cell Plasticity

    Adult stem cells offer great potential as tools or targets of new treatments, and the Stem Cell Network launched a multidisciplinary project early in its mandate in order to discover more about the nature of these mysterious cells.

    READ STORY

  • Blood Stem Cell Expansion

    Over more than a decade of targeted funding, the Stem Cell Network harnessed the strength of world-leading Canadian researchers to develop technologies to increase quantities of blood stem cells for expanded therapeutic use and to overcome a significant hurdle in the delivery of cell-based treatments to patients.

    READ STORY

  • Evidence-Based Policy Making

    When the Stem Cell Network launched in 2001, its most pressing goal was to address the policy vacuum that was constraining stem cell research in Canada. SCN and its members provided credible, research-based evidence and recommendations that were critical in the development of Canada’s regulatory landscape for stem cell research.

    READ STORY